eMedicine Specialties > Oncology > Carcinomas of the Central and Peripheral Nervous System

Astrocytoma

Author: Benjamin Kennedy, BA, Columbia University College of Physicians and Surgeons
Coauthor(s): Jeffrey N Bruce, MD, Edgar M Housepian Professor of Neurological Surgery Research, Professor of Neurological Surgery, Director of Brain Tumor Tissue Bank, Director of Bartoli Brain Tumor Laboratory, Department of Neurosurgery, Columbia University College of Physicians and Surgeons
Contributor Information and Disclosures

Updated: Jan 23, 2009

Introduction

Background

Astrocytomas are CNS neoplasms in which the predominant cell type is derived from an immortalized astrocyte.1 Two classes of astrocytic tumors are recognized—those with narrow zones of infiltration (eg, pilocytic astrocytoma, subependymal giant cell astrocytoma, pleomorphic xanthoastrocytoma) and those with diffuse zones of infiltration (eg, low-grade astrocytoma, anaplastic astrocytoma, glioblastoma). Members of the latter group share various features, including the ability to arise at any site in the CNS, with a preference for the cerebral hemispheres; clinical presentation usually in adults; heterogeneous histopathological properties and biological behavior; diffuse infiltration of contiguous and distant CNS structures, regardless of histological stage; and an intrinsic tendency to progress to more advanced grades.


Gross specimen of a low-grade astrocytoma.

Gross specimen of a low-grade astrocytoma.

[ CLOSE WINDOW ]
Gross specimen of a low-grade astrocytoma.

Gross specimen of a low-grade astrocytoma.


Numerous grading schemes based on histopathologic characteristics have been devised, including the Bailey and Cushing grading system, Kernohan grades I-IV, World Health Organization (WHO) grades I-IV, and St. Anne/Mayo grades 1-4. Regions of a tumor demonstrating the greatest degree of anaplasia are used to determine the histologic grade of the tumor. This practice is based on the assumption that the areas of greatest anaplasia determine disease progression.

This article focuses on the widely accepted WHO grading scheme that relies on assessments of nuclear atypia, mitotic activity, cellularity, vascular proliferation, and necrosis.2 WHO grade I corresponds to pilocytic astrocytoma, WHO grade II corresponds to low-grade (diffuse) astrocytoma, WHO grade III corresponds to anaplastic astrocytoma, and WHO grade IV corresponds to glioblastoma multiforme (GBM). This article is confined to low-grade and anaplastic astrocytomas. GBM and pilocytic astrocytoma are not discussed in this article (for more information, see Glioblastoma Multiforme).

Pathophysiology

Regional effects of astrocytomas include compression, invasion, and destruction of brain parenchyma. Arterial and venous hypoxia, competition for nutrients, release of metabolic end products (eg, free radicals, altered electrolytes, neurotransmitters), and release and recruitment of cellular mediators (eg, cytokines) disrupt normal parenchymal function. Elevated intracranial pressure (ICP) attributable to direct mass effect, increased blood volume, or increased cerebrospinal fluid (CSF) volume may mediate secondary clinical sequelae. Neurological signs and symptoms attributable to astrocytomas result from perturbation of CNS function. Focal neurological deficits (eg, weakness, paralysis, sensory deficits, cranial nerve palsies) and seizures of various characteristics may permit localization of lesions.

Infiltrating low-grade astrocytomas grow slowly compared to their malignant counterparts. Doubling time for low-grade astrocytomas is estimated at 4 times that of anaplastic astrocytomas. Several years often intervene between the initial symptoms and the establishment of a diagnosis of low-grade astrocytoma. One recent series estimated the interval to be approximately 3.5 years. The clinical course is marked by a gradual deterioration in half of cases, a stepwise decline in one third of cases, and a sudden deterioration in 15% of cases. Seizures, often generalized, are the initial presenting symptom in about half of patients with low-grade astrocytoma.

For patients with anaplastic astrocytomas,3 the growth rate and interval between onset of symptoms and diagnosis is intermediate between low-grade astrocytomas and glioblastomas. Although highly variable, a mean interval of approximately 1.5-2 years between onset of symptoms and diagnosis is frequently reported. Compared to low-grade lesions, seizures are less common among patients with anaplastic astrocytomas. Initial presenting symptoms most commonly are headache, depressed mental status, and focal neurological deficits.

Frequency

United States

The annual incidence of glioma in the United States is 5.4 cases per 100,000 population. 

International

Incidence differences are not significant between the United States and other countries. 

Mortality/Morbidity

Morbidity and mortality, as defined by the length of a patient's history and the odds of recurrence-free survival, are correlated most highly with the intrinsic properties of the astrocytoma in question. Typical ranges of survival are approximately 10 years from the time of diagnosis for pilocytic astrocytomas (WHO grade I), more than 5 years for patients with low-grade diffuse astrocytomas (WHO grade II),4 2-5 years for those with anaplastic astrocytomas (WHO grade III), and less than 1 year for patients with glioblastoma (WHO grade IV).

Race

Although genetic determinants are recognized in astrocytoma development and progression, astrocytomas do not differ intrinsically in incidence or behavior among racial groups. Demographic and sociological factors, such as population, age, ethnic attitude toward disease, and access to care, have been reported to influence measured distributions.

Sex

No clear sex predominance has been identified in the development of pilocytic astrocytomas. A slight male predominance, with a male-to-female ratio of 1.18:1 for development of low-grade astrocytomas, has been reported. A more significant male predominance, with a male-to-female ratio of 1.87:1 for the development of anaplastic astrocytomas, has been identified.

Age

Most cases of pilocytic astrocytoma present in the first 2 decades of life. In contrast, the peak incidence of low-grade astrocytomas, representing 25% of all cases in adults, occurs in people aged 30-40 years. Ten percent of low-grade astrocytomas occur in people younger than 20 years; 60% of low-grade astrocytomas occur in people aged 20-45 years; and 30% of low-grade astrocytomas occur in people older than 45 years. The mean age of patients undergoing a biopsy of anaplastic astrocytoma is 41 years.

Clinical

History

The type of neurological symptoms that result from astrocytoma development depends foremost on the site and extent of tumor growth in the CNS. Reports of altered mental status, cognitive impairment, headaches, visual disturbances, motor impairment, seizures, sensory anomalies, or ataxia in the patient's history should alert the clinician to the presence of a neurological disorder and should indicate a requirement for further studies. In this event, radiographic imaging, such as CT scan and MRI (with and without contrast), is indicated. Astrocytomas of the spinal cord or brainstem are less common and present with motor/sensory or cranial nerve deficits referable to the tumor's location.

Physical

  • A detailed neurological examination is required for the proper evaluation of any patient with an astrocytoma. Because these tumors may affect any part of the CNS, including the spinal cord, and may spread to distant regions of the CNS, a thorough physical examination referable to the entire neuraxis is necessary to define the location and extent of disease.
  • Special attention should be paid to signs of increased ICP, such as headache, nausea and vomiting, decreased alertness, cognitive impairment, papilledema, or ataxia, to determine the likelihood of mass effect, hydrocephalus, and herniation risk. Localizing and lateralizing signs, including cranial nerve palsies, hemiparesis, sensory levels, alteration of deep tendon reflexes (DTRs), and the presence of pathological reflexes (eg, Hoffman and Babinski signs), should be noted. Once neurological abnormalities are identified, imaging studies should be sought for further evaluation.

Causes

  • The etiology of diffuse astrocytomas has been the subject of analytic epidemiological studies that have yielded associations with various disorders and exposures.5 With the exception of therapeutic irradiation6 and, perhaps, nitroso compounds (eg, nitrosourea), the identification of specific causal environmental exposures or agents has been unsuccessful.  Although some concern has been raised regarding cell phone use as a potential risk factor for development of gliomas, the largest studies have not supported this.7,8,9,10,11
  • Children receiving prophylactic irradiation for acute lymphatic leukemia (ALL), for example, have a 22-fold increased risk of developing CNS neoplasms in WHO grade II, III, and IV astrocytomas, with an interval for onset of 5-10 years. Furthermore, irradiation of pituitary adenomas has been demonstrated to carry a 16-fold increased risk of glioma formation.12
  • Evidence exists for genetic susceptibility to glioma development. For example, familial clustering of astrocytomas is well described in inherited neoplastic syndromes, such as Turcot syndrome, neurofibromatosis type 1 (NF1) syndrome, and p53 germ line mutations (eg, Li-Fraumeni syndrome).
  • Biological investigation has implicated that mutations in specific molecular pathways, such as the p53-MDM2-p21 and p16-p15-CDK4-CDK6-RB pathways, are associated with astrocytoma development and progression. In addition, inherited elements of the immune response known as human leukocyte antigens (HLA) have been both positively and negatively associated with an increased risk for the development of glioblastoma multiforme.  Two-thirds of low-grade astrocytomas have p53 mutations.13  
  • Recently, attempts have been made to determine prognosis and response to various treatment modalities based on the individual pattern of genetic changes in a particular patient. For example, patients with oligodendrogliomas that exhibit chromosomal changes at band 1p19q are known to have improved responses to the procarbazine, CCNU, vincristine (PCV) regimen of chemotherapy. Efforts are underway to identify similar unique susceptibilities associated with other commonly altered genes and proteins in astrocytomas. Other groups are working on developing models that will allow for a more accurate assessment of prognosis based on a combination of molecular profiling of the tumors and clinical characteristics of the patient.

More on Astrocytoma

Overview: Astrocytoma
Differential Diagnoses & Workup: Astrocytoma
Treatment & Medication: Astrocytoma
Follow-up: Astrocytoma
Multimedia: Astrocytoma
References
[ CLOSE WINDOW ]

References

  1. Greenberg MS. Astrocytoma. In: Handbook of Neurosurgery. Vol 1. 4th ed. Lakeland, Fla: Greenberg Graphics Inc; 1997:244-256.

  2. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol. Jul 1993;3(3):255-68. [Medline].

  3. Davis RL, Kleihues P, Burger PC. Anaplastic Astrocytoma. In: Kleihues P, Cavenee WK, eds. Pathology and Genetics: Tumours of the Nervous System. Lyon, France: International Agency for Cancer Research; 1997:14-15.

  4. Kleihues P, Davis RL, Ohgaki H. Low-grade diffuse astrocytoma. In: Kleihues P, Cavenee WK, eds. Pathology and Genetics: Tumours of the Nervous System. Lyon, France: International Agency for Cancer Research; 1997:10-14.

  5. Cavenee WK, Bigner DD, Newcomb EW. Diffuse astrocytomas. In: Kleihues P, Cavenee WK, eds. Pathology and Genetics: Tumours of the Nervous System. Lyon, France: International Agency for Cancer Research; 1997:2-9.

  6. Cavin LW, Dalrymple GV, McGuire EL, Maners AW, Broadwater JR. CNS tumor induction by radiotherapy: a report of four new cases and estimate of dose required. Int J Radiat Oncol Biol Phys. Feb 1990;18(2):399-406. [Medline].

  7. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. Jul 31 2008;359(5):492-507. [Medline]. [Full Text].

  8. Fisher JL, Schwartzbaum JA, Wrensch M, Wiemels JL. Epidemiology of brain tumors. Neurol Clin. Nov 2007;25(4):867-90, vii. [Medline]. [Full Text].

  9. Hardell L, Carlberg M, Soderqvist F, Mild KH, Morgan LL. Long-term use of cellular phones and brain tumours: increased risk associated with use for > or =10 years. Occup Environ Med. Sep 2007;64(9):626-32. [Medline]. [Full Text].

  10. Lahkola A, Auvinen A, Raitanen J, Schoemaker MJ, Christensen HC, Feychting M. Mobile phone use and risk of glioma in 5 North European countries. Int J Cancer. Apr 15 2007;120(8):1769-75. [Medline]. [Full Text].

  11. Inskip PD, Tarone RE, Hatch EE, Wilcosky TC, Shapiro WR, Selker RG. Cellular-telephone use and brain tumors. N Engl J Med. Jan 11 2001;344(2):79-86. [Medline]. [Full Text].

  12. Brüstle O, Ohgaki H, Schmitt HP, Walter GF, Ostertag H, Kleihues P. Primitive neuroectodermal tumors after prophylactic central nervous system irradiation in children. Association with an activated K-ras gene. Cancer. May 1 1992;69(9):2385-92. [Medline].

  13. Chawengchao B, Petmitr S, Ponglikitmongkol M, Chanyavanich V, Sangruji T, Theerapuncharoen V. Detection of a novel point mutation in the p53 gene in grade II astrocytomas by PCR-SSCP analysis with additional Klenow treatment. Anticancer Res. Jul-Aug 2001;21(4A):2739-43. [Medline]. [Full Text].

  14. Helseth A, Mørk SJ. Neoplasms of the central nervous system in Norway. III. Epidemiological characteristics of intracranial gliomas according to histology. APMIS. Jun 1989;97(6):547-55. [Medline].

  15. Sathornsumetee S, Rich JN, Reardon DA. Diagnosis and treatment of high-grade astrocytoma. Neurol Clin. Nov 2007;25(4):1111-39, x. [Medline]. [Full Text].

  16. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. Nov 1 2007;21(21):2683-710. [Medline]. [Full Text].

  17. van den Bent MJ. Anaplastic oligodendroglioma and oligoastrocytoma. Neurol Clin. Nov 2007;25(4):1089-109, ix-x. [Medline]. [Full Text].

  18. Butowski NA, Sneed PK, Chang SM. Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol. Mar 10 2006;24(8):1273-80. [Medline]. [Full Text].

  19. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. Sep 1999;17(9):2762-71. [Medline]. [Full Text].

  20. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. Aug 1999;17(8):2572-8. [Medline]. [Full Text].

  21. Walker MD. Adjuvant therapy for brain tumor. Int Adv Surg Oncol. 1980;3:351-69. [Medline]. [Full Text].

  22. Brown PD. Low-grade gliomas: the debate continues. Curr Oncol Rep. Jan 2006;8(1):71-7. [Medline]. [Full Text].

  23. Walker DA, Punt JA, Sokal M. Clinical management of brain stem glioma. Arch Dis Child. Jun 1999;80(6):558-64. [Medline]. [Full Text].

  24. Littman P, Jarrett P, Bilaniuk LT, Rorke LB, Zimmerman RA, Bruce DA. Pediatric brain stem gliomas. Cancer. Jun 1 1980;45(11):2787-92. [Medline]. [Full Text].

  25. Berger MS, Edwards MS, LaMasters D, Davis RL, Wilson CB. Pediatric brain stem tumors: radiographic, pathological, and clinical correlations. Neurosurgery. Mar 1983;12(3):298-302. [Medline]. [Full Text].

  26. Epstein F, Wisoff JH. Intrinsic brainstem tumors in childhood: surgical indications. J Neurooncol. Dec 1988;6(4):309-17. [Medline]. [Full Text].

  27. Jallo GI, Biser-Rohrbaugh A, Freed D. Brainstem gliomas. Childs Nerv Syst. Mar 2004;20(3):143-53. [Medline]. [Full Text].

  28. Steck J, Friedman WA. Stereotactic biopsy of brainstem mass lesions. Surg Neurol. Jun 1995;43(6):563-7; discussion 567-8. [Medline]. [Full Text].

  29. Rajshekhar V, Chandy MJ. Computerized tomography-guided stereotactic surgery for brainstem masses: a risk-benefit analysis in 71 patients. J Neurosurg. Jun 1995;82(6):976-81. [Medline]. [Full Text].

  30. Albright AL, Price RA, Guthkelch AN. Brain stem gliomas of children. A clinicopathological study. Cancer. Dec 15 1983;52(12):2313-9. [Medline]. [Full Text].

  31. Amundson EW, McGirt MJ, Olivi A. A contralateral, transfrontal, extraventricular approach to stereotactic brainstem biopsy procedures. Technical note. J Neurosurg. Mar 2005;102(3):565-70. [Medline]. [Full Text].

  32. Kaplan AM, Albright AL, Zimmerman RA, Rorke LB, Li H, Boyett JM. Brainstem gliomas in children. A Children's Cancer Group review of 119 cases. Pediatr Neurosurg. 1996;24(4):185-92. [Medline]. [Full Text].

  33. Tomita T, McLone DG, Naidich TP. Brain stem gliomas in childhood. Rational approach and treatment. J Neurooncol. 1984;2(2):117-22. [Medline]. [Full Text].

  34. Albright AL. Tumors of the pons. Neurosurg Clin N Am. Jul 1993;4(3):529-36. [Medline]. [Full Text].

  35. Epstein F. Intrinsic brain stem tumors of childhood. Surgical indications. Prog Exp Tumor Res. 1987;30:160-9. [Medline]. [Full Text].

  36. Mandell LR, Kadota R, Freeman C, Douglass EC, Fontanesi J, Cohen ME. There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys. Mar 15 1999;43(5):959-64. [Medline]. [Full Text].

  37. Packer RJ, Boyett JM, Zimmerman RA, Albright AL, Kaplan AM, Rorke LB. Outcome of children with brain stem gliomas after treatment with 7800 cGy of hyperfractionated radiotherapy. A Childrens Cancer Group Phase I/II Trial. Cancer. Sep 15 1994;74(6):1827-34. [Medline]. [Full Text].

  38. Fischbein NJ, Prados MD, Wara W, Russo C, Edwards MS, Barkovich AJ. Radiologic classification of brain stem tumors: correlation of magnetic resonance imaging appearance with clinical outcome. Pediatr Neurosurg. 1996;24(1):9-23. [Medline]. [Full Text].

  39. Allen JC, Siffert J. Contemporary chemotherapy issues for children with brainstem gliomas. Pediatr Neurosurg. 1996;24(2):98-102. [Medline]. [Full Text].

  40. Recinos PF, Sciubba DM, Jallo GI. Brainstem tumors: where are we today?. Pediatr Neurosurg. 2007;43(3):192-201. [Medline]. [Full Text].

  41. Laws ER Jr, Taylor WF, Clifton MB, Okazaki H. Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J Neurosurg. Oct 1984;61(4):665-73. [Medline].

  42. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. Aug 2001;95(2):190-8. [Medline]. [Full Text].

  43. Albright AL. Diffuse brainstem tumors: when is a biopsy necessary?. Pediatr Neurosurg. 1996;24(5):252-5. [Medline]. [Full Text].

  44. Kleihues P, Kiessling M, Janzer RC. Morphological markers in neuro-oncology. Curr Top Pathol. 1987;77:307-38. [Medline].

  45. Levy LF, Auchterlonie WC. Primary cerebral neoplasia in Rhodesia. Int Surg. May 1975;60(5):286-92. [Medline].

  46. Tatter BS, Wilson CB, Harsh GR. Neuroepithelial tumors of the adult brain. In: Youman's Neurological Surgery. 4th ed. Philadelphia, Pa: WB Saunders Company; 1996:2612-2684.

  47. Zhou YH, Hess KR, Liu L, Linskey ME, Yung WK. Modeling prognosis for patients with malignant astrocytic gliomas: quantifying the expression of multiple genetic markers and clinical variables. Neuro Oncol. Oct 2005;7(4):485-94. [Medline]. [Full Text].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

low-grade astrocytoma, fibrillary astrocytoma, gemistocytic astrocytoma, protoplasmic astrocytoma, diffuse astrocytoma, pilocytic astrocytoma, pilocystic astrocytoma, juvenile pilocytic astrocytoma, anaplastic astrocytoma, glioblastoma multiforme, CNS neoplasm, CNS cancer, CNS malignancy, immortalized astrocyte

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Benjamin Kennedy, BA, Columbia University College of Physicians and Surgeons
Disclosure: Nothing to disclose.

Coauthor(s)

Jeffrey N Bruce, MD, Edgar M Housepian Professor of Neurological Surgery Research, Professor of Neurological Surgery, Director of Brain Tumor Tissue Bank, Director of Bartoli Brain Tumor Laboratory, Department of Neurosurgery, Columbia University College of Physicians and Surgeons
Jeffrey N Bruce, MD is a member of the following medical societies: American Association for the Advancement of Science, American Association of Neurological Surgeons, Congress of Neurological Surgeons, New York Academy of Sciences, North American Skull Base Society, Society for Neuro-Oncology, and Southwest Oncology Group
Disclosure: NIH Grant/research funds Other

Medical Editor

Robert C Shepard, MD, FACP, Associate Professor of Medicine in Hematology and Oncology at University of North Carolina at Chapel Hill; Vice President of Scientific Affairs, Therapeutic Expertise, Oncology, at PRA International
Robert C Shepard, MD, FACP is a member of the following medical societies: American Association for Cancer Research, American College of Physician Executives, American College of Physicians, American Federation for Clinical Research, American Federation for Medical Research, American Medical Association, American Medical Informatics Association, American Society of Hematology, Association of Clinical Research Professionals, Eastern Cooperative Oncology Group, European Society for Medical Oncology, Massachusetts Medical Society, and Society for Biological Therapy
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

CME Editor

Rajalaxmi McKenna, MD, FACP, Consulting Staff, Department of Medicine, Southwest Medical Consultants, SC, Good Samaritan Hospital, Advocate Health Systems
Rajalaxmi McKenna, MD, FACP is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology, and International Society on Thrombosis and Haemostasis
Disclosure: Nothing to disclose.

Chief Editor

Jules E Harris, MD, Clinical Professor of Medicine, Division of Hematology/Medical Oncology, Department of Internal Medicine, University of Arizona College of Medicine at Tucson; Consulting Staff, Arizona Cancer Center
Jules E Harris, MD is a member of the following medical societies: American Association for Cancer Research, American Association for the Advancement of Science, American Association of Immunologists, American Society of Hematology, and Central Society for Clinical Research
Disclosure: GlobeImmune Salary Consulting; Amplimed Consulting fee Consulting

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.